argenx SE (ARGX) Surges to Record High, Is Now Top Performer

April 17, 2018 - By Stephen Andrade

The stock of argenx SE (NASDAQ:ARGX) reached all time high today, Apr, 17 and still has $92.74 target or 7.00 % above today’s $86.67 share price. This indicates more upside for the $2.75B company. This technical setup was reported by If the $92.74 PT is reached, the company will be worth $192.36M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 1.90% or $1.62 during the last trading session, reaching $86.67. About 77,757 shares traded. argenx SE (NASDAQ:ARGX) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer. The company has market cap of $2.75 billion. The companyÂ’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It currently has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

argenx SE (NASDAQ:ARGX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.